NCT04936178CompletedPhase 1/2
A Study of NB003 in Patients With Advanced Malignancies
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Jul 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 1 Mar 2023
- Start date
- 19 Oct 2023
- Lead sponsor
- Ningbo Newbay Technology Development Co. Ltd.
- Diseases
- Melanoma
- NCT number
- NCT04936178
- EU CT number
- 2022-502401-15-00
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 37
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Completed |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.